2Shiraki K, Tsuji N, Shioda T, et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas[J]. Proc Natl Acad Sci USA, 1997,94:6420.
3Muller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-l/Fas) receptor/ligand system and involves activation of wild-type p53[J]. J Clin Invest, 1997,99:403.
4Reybar U, Strater J, Kittstein W, et al. Colon carcinoma cell use different mechanism to escape CD95-mediated apoptosis[J]. Cancer Res, 1998,58:526.
5Salo T, Irre S, Kitada S, et al. FAP-1: a protein lyrosine phosphalase that associates with Fas[J]. Science,1995,268:411.
6Lee SH, Shin MS, Park WS, et al. Immunohistochemical localization of FAP-1, an inhibitor of Fas-mediated apoptosis, in normal and neoplastic human tissues[J]. APMIS, 1999,107:1101.
7Ungefroren H, Voss M, Bernstorff WV, et al. Immunological escape mechanisms in pancreatic carcinoma [J].Ann Acad Sci, 1999,880:243.
8Itakura M, Mort S, Park NH, et al. Both H PV and carcinogen contribute to the development of resistance to apoptosis during oral carcinogenesis[J]. Oncology, 2000,16: 591.
9Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells[J]. Lab Invest, 1993, 69:415.
10Bennett MW, O′connell J, L′sullivan GC, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma [J]. Immunotherapy,1998,48(160) :5669.
